Certa Therapeutics

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli

Australian biotechs Certa Therapeutics and OccuRx are combining their assets under one company in a bid to become a leading player in the fibrotic diseases space. Certa’s acquisition of fellow Melbo

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up

Certa Therapeutics ’ lead candidate, FT011, has hit the mark in a Phase II scleroderma trial, sparking Phase III plans as the firm edges closer to validating its approach of targeting an undrugged rec